How does Ocaliva (obeticholic acid) work in the body?
Ocaliva is obeticholic acid, a bile acid–derived medicine. Its mechanism of action centers on activating the farnesoid X receptor (FXR), a nuclear receptor that helps regulate bile acid synthesis and transport in the liver and intestine [1]. When FXR is activated, the body shifts bile acid production and bile flow patterns in a way that can reduce cholestatic liver injury [1].
What does FXR activation change for bile acids and bile flow?
FXR activation affects the pathways that control:
- Bile acid synthesis in the liver
- Cholesterol and bile acid transport processes
- Signals that influence how bile acids move through the hepatobiliary system [1]
In cholestatic conditions, these effects are intended to improve bile flow and lower bile-acid–related stress on the liver by modifying bile acid handling [1].
How is this different from bile acid replacements or other cholestasis therapies?
Ocaliva is not a bile acid replacement. It works by directly activating a bile-acid–responsive receptor (FXR) that regulates bile acid homeostasis at the signaling level [1]. Other cholestasis treatments may act through different receptors or mechanisms (for example, transporters or downstream inflammatory pathways), so their effects and targets can differ from Ocaliva’s FXR-driven pathway [1].
What conditions is Ocaliva used for based on its mechanism?
Ocaliva’s FXR-targeting mechanism is used in clinical settings where improving cholestasis and bile acid dysregulation is central to the disease process, including primary biliary cholangitis (PBC) [1].
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206908